DK2723369T4 - Sammensætning og formulering omfattende rekombinant humant iduronat-2-sulfatase og fremgangsmåde til fremstilling deraf - Google Patents

Sammensætning og formulering omfattende rekombinant humant iduronat-2-sulfatase og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK2723369T4
DK2723369T4 DK12803297.6T DK12803297T DK2723369T4 DK 2723369 T4 DK2723369 T4 DK 2723369T4 DK 12803297 T DK12803297 T DK 12803297T DK 2723369 T4 DK2723369 T4 DK 2723369T4
Authority
DK
Denmark
Prior art keywords
sulfatase
comprehensively
formulation
manufacture
composition
Prior art date
Application number
DK12803297.6T
Other languages
English (en)
Other versions
DK2723369T3 (da
Inventor
Thong-Gyu Jin
Yo Kyung Chung
Sang Hoon Paik
Yoo Chang Park
Jinwook Seo
Yong Woon Choi
Jong Mun Son
Yong-Chul Kim
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2723369(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of DK2723369T3 publication Critical patent/DK2723369T3/da
Application granted granted Critical
Publication of DK2723369T4 publication Critical patent/DK2723369T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
DK12803297.6T 2011-06-24 2012-06-15 Sammensætning og formulering omfattende rekombinant humant iduronat-2-sulfatase og fremgangsmåde til fremstilling deraf DK2723369T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (2)

Publication Number Publication Date
DK2723369T3 DK2723369T3 (da) 2016-06-13
DK2723369T4 true DK2723369T4 (da) 2023-07-24

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12803297.6T DK2723369T4 (da) 2011-06-24 2012-06-15 Sammensætning og formulering omfattende rekombinant humant iduronat-2-sulfatase og fremgangsmåde til fremstilling deraf

Country Status (28)

Country Link
US (2) US9206402B2 (da)
EP (1) EP2723369B2 (da)
JP (2) JP5844459B2 (da)
KR (2) KR101158673B1 (da)
CN (1) CN103635203B (da)
AU (2) AU2012274215B2 (da)
BR (1) BR112013032193A2 (da)
CA (1) CA2839674C (da)
CO (1) CO6862105A2 (da)
CY (1) CY1117861T1 (da)
DK (1) DK2723369T4 (da)
EA (1) EA026499B1 (da)
ES (1) ES2575377T5 (da)
FI (1) FI2723369T4 (da)
HK (1) HK1195731A1 (da)
HR (1) HRP20160490T4 (da)
HU (1) HUE027431T2 (da)
IL (1) IL230120B (da)
MX (1) MX341946B (da)
MY (1) MY166647A (da)
PE (1) PE20140734A1 (da)
PL (1) PL2723369T5 (da)
PT (1) PT2723369E (da)
RS (1) RS54822B2 (da)
SI (1) SI2723369T2 (da)
SM (1) SMT201600194B (da)
UA (1) UA109949C2 (da)
WO (1) WO2012177020A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业(上海)股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20190136271A (ko) 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
EA026499B1 (ru) 2017-04-28
EA201490149A1 (ru) 2014-09-30
CY1117861T1 (el) 2017-05-17
JP2016056179A (ja) 2016-04-21
AU2016201487B2 (en) 2017-10-19
KR101158673B1 (ko) 2012-07-03
EP2723369A4 (en) 2014-12-24
SMT201600194B (it) 2016-08-31
EP2723369B2 (en) 2023-05-10
UA109949C2 (uk) 2015-10-26
MY166647A (en) 2018-07-18
CA2839674C (en) 2018-04-24
ES2575377T5 (es) 2023-10-26
US20150320843A1 (en) 2015-11-12
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
PT2723369E (pt) 2016-06-03
MX341946B (es) 2016-09-08
CN103635203A (zh) 2014-03-12
RS54822B1 (sr) 2016-10-31
WO2012177020A3 (en) 2013-04-04
SI2723369T1 (sl) 2016-09-30
AU2012274215A1 (en) 2014-02-20
CN103635203B (zh) 2016-06-08
BR112013032193A2 (pt) 2017-11-21
EP2723369A2 (en) 2014-04-30
PE20140734A1 (es) 2014-07-04
JP6000432B2 (ja) 2016-09-28
KR20160030591A (ko) 2016-03-21
HUE027431T2 (en) 2016-09-28
US20140242059A1 (en) 2014-08-28
AU2012274215B2 (en) 2015-12-10
DK2723369T3 (da) 2016-06-13
US9206402B2 (en) 2015-12-08
US9249397B2 (en) 2016-02-02
MX2013015127A (es) 2014-06-11
HK1195731A1 (zh) 2014-11-21
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
KR101910124B1 (ko) 2018-10-19
HRP20160490T1 (hr) 2016-08-12
IL230120B (en) 2020-09-30
WO2012177020A9 (en) 2013-02-14
PL2723369T5 (pl) 2024-02-05
ES2575377T3 (es) 2016-06-28
NZ620284A (en) 2015-11-27
JP2014520143A (ja) 2014-08-21
HRP20160490T4 (hr) 2023-09-15
CO6862105A2 (es) 2014-02-10
EP2723369B1 (en) 2016-04-13
JP5844459B2 (ja) 2016-01-20
SI2723369T2 (sl) 2023-08-31

Similar Documents

Publication Publication Date Title
DK2723369T4 (da) Sammensætning og formulering omfattende rekombinant humant iduronat-2-sulfatase og fremgangsmåde til fremstilling deraf
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2941220T3 (da) Anordning og fremgangsmåde til subgingival måling
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK3586861T3 (da) Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
DK2928921T3 (da) Sammensætninger og fremgangsmåder til antistoffer målrettet epo
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
BR112014010450A2 (pt) composição e método
NO345087B1 (no) System og fremgangsmåte for forspenning av stigerør
HK1203438A1 (en) Method and device for fast dissolution of solid protein composition
DK2771022T3 (da) Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK2492520T3 (da) Fastgørelsesstift og fremgangsmåde til fremstilling deraf
DK3381461T3 (da) Peptider og fremgangsmåder til anvendelse deraf
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
DK2559266T3 (da) Rf-fordelingssystem og fremgangsmåde til anvendelse deraf